

# Register

A joint project of the Sylvester Comprehensive Cancer Center  
and the Florida Department of Health

Division of Cancer Prevention and Control

Volume 32, 2006

## Once again the State of Florida has received the highest certification a statewide, population-based cancer registry can receive.... GOLD !!!!

**T**he Florida Cancer Data System (FCDS), Florida's legislatively mandated, statewide, population-based incidence registry is a joint project of the University of Miami Miller School of Medicine, Florida Department of Health, the Centers for Disease Control and Florida's facility based cancer registries. Cases in the FCDS database are submitted from hospitals, free-standing ambulatory surgical facilities, radiation therapy facilities, private physicians and death certificates. FCDS is part of the Centers for Disease Control National Program of Cancer Registries (CDC/NPCR) and for the fourth year in a row, has been nationally certified by the North American Association of Central Cancer Registries (NAACCR) at its highest level, 'gold certification'. Gold certification is conferred on central

registries that meet or exceed all standards for completeness, timeliness and quality.

In addition to the gold certification, Florida was one of only four states in the nation to be singled out at the CDC Program Directors meeting in March for achieving **all** the CDC/NPCR program objectives. The reason for our continued success is the partnership established in 1981 between the Florida Department of Health, the University of Miami and the cancer data management professionals in Florida.

On behalf of Dr. Youjie Huang and Ms. Tara Hylton at the Florida Department of Health, Drs. Lora Fleming and Edward Trapido and all the FCDS staff at the UM and Mr. Ryan Intlekofer at the CDC, I thank you for your dedication and professionalism. Your continued commitment to cancer registration in Florida has made us one of the best cancer

surveillance systems in the nation.

A copy of the certificate has been placed on page 2 and the FCDS web site at <http://fcds.med.miami.edu>. We encourage you to download it and display it. You have worked very hard for this and should be recognized for your efforts by your respective institution.

*By Jill A. MacKinnon, PhD,  
CTR*

### Inside this issue:

NAACCR Gold Certification	1
NAACCR Certificate	2
Dr Lora Fleming	3
NAACCR Version 11	4
Calendar of Events	5
Completeness Report	6

(Continued from page 1: Once again the State of Florida has received the highest certification a statewide, population-based cancer registry can receive... GOLD!!!)

# North American Association of Central Cancer Registries



The Board of Directors certifies that  
**Florida Cancer Data System**  
has attained the  
**NAACCR Gold Standard**  
for Quality, Completeness, and Timeliness

*Betsy A. Kohler*

President, NAACCR

*May 18, 2006*

Date





## USF Names UM Epidemiologist 2006 Florida Outstanding Woman in Public Health



University of Miami epidemiologist Dr. Lora E. Fleming has been named the Florida Outstanding Woman in Public Health for 2006 by the University of South Florida College of Public Health.

The College bestows the award each year on a woman whose career accomplishments and leadership have contributed significantly to the field of public health in Florida. Dr. Fleming was honored at an awards ceremony Wednesday, at the USF College of Public Health in Tampa, Fla.

Dr. Fleming is a professor in the Department of Epidemiology and Public Health at the University of Miami's Miller School of Medicine and holds a joint appointment in the Rosenstiel School of Marine and Atmospheric Science. She earned a joint MD-MPH degree from Harvard Medical School and Harvard School of Public Health. She completed her residency in family practice at Montefiore Hospital in Bronx, N.Y., and earned a PhD in epidemiology from Yale Public Health School.

Dr. Fleming studies the environmental toxicity of algal blooms on human health. She has been instrumental in promoting occupational and environmental health at the local, state and national levels.

"Dr. Fleming is never too busy to field anxious 'cold' calls from workers or other community members concerned about asbestos worksite exposures or possible local cancer cluster in the state. Her advice is always scientifically-based, clearly delivered and never patronizing," said Dr. David Lee, a colleague at the University of Miami School of Medicine who has worked with Dr. Fleming on several studies funded by the National Institute for Occupational Safety and Health and other agencies.

*The Florida Outstanding Woman in Public Health Award was initiated by USF in 1988, and nominations are solicited from public health practitioners across the state. Past honorees include Dr. Lillian Stark, director of virology at the Florida Department of Health Tampa Branch Laboratory and Dr. Jean Malecki, director of the Palm Beach County Health Department.*

## Statement from the National Cancer Institute on FDA Approval of the HPV Vaccine

### *Collaborative science at NCI led to invention of technology for HPV vaccine*

Nearly two decades ago, researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and other institutions began searching for the underlying causes of cervical cancer. That scientific quest led to today's approval by the Food and Drug Administration of the vaccine Gardasil™, which protects against infection from the two types of human papillomavirus (HPV) that cause the majority of cervical cancers worldwide.

Population studies helped to establish the link between HPV infections and the disease, revealing that while most HPV infections clear and do not lead to cancer, virtually all cases of cervical cancer were caused by HPV infection. NCI scientists Douglas Lowy, M.D., and John Schiller, Ph.D., pioneers in HPV research, then examined ways to boost the body's immune response to prevent the cancer-causing infection. This work led to the development of the technology on which the HPV vaccine is based.



"Genetic engineering - technology involving the manipulation of genetic material - was used to create this vaccine, which is made up of non-infectious virus-like particles (VLPs)," explained Lowy, chief of the Laboratory of Cellular Oncology in NCI's Center for Cancer Research (CCR). "These hollow spheres, formed by a single protein from the virus (L1 protein), trigger an antibody response that is capable of protecting the body against infection by the targeted virus types."

"Gardasil is similar to other immunizations that guard against viral infection," said Schiller, deputy chief of the Laboratory of Cellular Oncology in CCR. "By preventing infection with two of the HPV types that can cause cervical cancer, this vaccine, if given prior to exposure to these sexually transmitted viruses, can protect women from ultimately developing cervical cancer."

"This vaccine opens a new era in cancer prevention," said NCI Acting Director John E. Niederhuber, M.D. "It has the potential to save women's lives, as well as to reduce health disparities in the United States and around the world."

Niederhuber added, "NCI's immunology and vaccine research regarding HPV infection is far from finished. We continue to work on improved vaccines and immunization technology, to make these prevention strategies even more effective and accessible to women worldwide."

HPVs not targeted by the current vaccines also can cause cervical cancer; women should continue to be screened with a Pap test or an approved alternative screening method.

*Additional information about HPV, vaccines, and cervical cancer is available at <http://www.cancer.gov/cancertopics/hpv-vaccines>.*

*For more information about cancer, please visit the NCI Web site at <http://www.cancer.gov>, or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).*

# NAACCR V11 – TIMETABLE CONVERSION



FCDS will be converting the existing database to the new NAACCR Version 11 record layout according to national standards for data collection. All the cases after the conversion, regardless of their admission or diagnosis date (including "historical" cases) must be submitted to FCDS in the Version 11 format. In the new format, FCDS will be collecting thirteen additional fields. These fields are listed below. There will also be new edit checks to validate the newly collected fields. In addition, all reporting facilities that use a software vendor to submit data to FCDS through the FCDS upload program will be required to upload ten cases as a test and mail along to FCDS printouts of the uploaded cases for approval. The test is to assure that the cases are being submitted in the correct Version 11 record layout. Those facilities that use the FCDS IDEA single entry program will not be required to submit test cases. Please refer to the timetable below. FCDS will make every attempt to get all conversions worked out before the scheduled date in order to be able to process data sooner.

## Version 11 - Newly Collected Fields:

- |                              |                              |
|------------------------------|------------------------------|
| 1. RX SUMM--SURG/RAD SEQ     | 8. RX TEXT--RADIATION (BEAM) |
| 2. RAD--REGIONAL RX MODALITY | 9. RX TEXT--RADIATION OTHER  |
| 3. RX SUMM--SYSTEMIC SUR SEQ | 10. RX TEXT--CHEMO           |
| 4. NAME--ALIAS               | 11. RX TEXT--HORMONE         |
| 5. ADDR AT DX-SUPPLEMENTL    | 12. RX TEXT--BRM             |
| 6. TEXT--PRIMARY SITE TITLE  | 13. RX TEXT--OTHER           |
| 7. TEXT--HISTOLOGY TITLE     |                              |

<b>FCDS CONVERSION TIMETABLE</b>	
<b><i>June 30<sup>th</sup>, 11:00pm</i></b>	Annual Reporting Deadline
<b><i>July 3<sup>rd</sup></i></b>	FCDS IDEA Single Entry program will be available in the Version 11 format. Facilities using a software vendor to submit cases to FCDS will be able to upload 10 test cases for approval (Field Coordinators must have the hard copy of the test cases for approval). Approved facilities will be able to upload regular cases.
<b><i>July 3<sup>rd</sup>-16<sup>th</sup></i></b>	FCDS will accept data, but it will not be processed by the Field Coordinators.
<b><i>July 7<sup>th</sup>, 5:00pm</i></b>	Field Coordinators will complete the process of all the data submitted in Version 10.2.
<b><i>July 7<sup>th</sup>, after 5:00pm</i></b>	FCDS will convert the database to the Version 11 format. FCDS will implement new edit checks.
<b><i>July 17<sup>th</sup></i></b>	The Field Coordinators will begin processing the cases in the Version 11 format.

Should you have any questions, please contact Meg Herna at 305-243-2625.

# CALENDAR OF EVENTS

CALENDAR OF EVENTS

## PRINCIPLES OF ONCOLOGY FOR CANCER REGISTRY PROFESSIONALS

**Dates:** July 17—21, 2006  
**Location:** Little Rock, Arkansas  
**Website:** <http://www.afritz.org/>

## FCRA ANNUAL CONFERENCE "Pathways to Progress"

**Dates:** July 25 – 26, 2006  
**Location:** Embassy Suites Hotel—Ft Myers  
 Estero, Florida  
**Website:** <http://fcra.org/>

## FCDS ANNUAL CONFERENCE

**Date:** July 27 – 28, 2006  
**Location:** Embassy Suites Hotel—Ft Myers  
 Estero, Florida  
**Website:** <http://fcds.med.miami.edu/>

## CTR EXAM INFORMATION

**Application Deadline:** July 31, 2006  
**Testing Begins:** September 16, 2006  
**Testing Ends:** September 30, 2006  
**Website:** [www.ncra-usa.org](http://www.ncra-usa.org)

*The Certification Examination will be administered during two 2-week testing periods on a daily basis, Monday through Saturday, excluding holidays, at LaserGrade Computer Testing Inc.'s computer-based testing facilities managed by Professional Testing Corporation.*

## CTR EXAM REVIEW & BASIC SKILLS WORKSHOPS

**Date:** August 24-25, 2006  
**Location:** Sarasota Memorial Hospital, Sarasota, FL  
**Contact:** Walter Sanford, CTR at 239-436-5212 or  
[walter.sanford@nchmd.org](mailto:walter.sanford@nchmd.org)



## Presented by NAACCR Hospital Registrars & Cancer Reporters Webinars


Eight Webinars – 4 hours each, beginning  
**October, 2006 – September, 2007**  
 Subscription for the entire series is \$800.00  
**Contact:** Shannon Vann, CTR  
 at [svann@naaccr.org](mailto:svann@naaccr.org) or (315) 682-6543

## FCDS 2006 IMPLEMENTATION GUIDE

The 5/19/2006 revisions to the FCDS 2006 Implementation Guide and Schedule for NAACCR Version 11 are now available on our website <http://fcds.med.miami.edu> under What's New.

These guides apply to facilities submitting full cancer abstracts to FCDS, not Path or RT identification data.

## Follow-up Inquiry Program



FCDS has implemented a new menu option under the FCDS IDEA called Follow-up Inquiry. The Follow-up Inquiry program was designed to assist the CoC approved cancer registries with their follow-up activities. The program will ask the user the Facility Number, the Accession Number, and Sequence Number. Once this information is validated in the FCDS master file, the program will retrieve the Vital Status, the Date of Last Contact or Date of Death, and the Cause of Death for that patient. The users that already have Web-based Report Access will automatically have access to the Follow-up Inquiry program. As the Facility Administrator or Cancer Registry Manager, if you wish other users to have access to the Follow-up Inquiry program, please complete the two forms, the *FCDS IDEA User Account Request Form* and the *Facility Level Data Access and Account Request memo*.

# COMPLETENESS REPORT 2005 CASE REPORTING

Month	Complete	Expected
November 2005	23%	41%
December 2005	31%	50%
January 2006	39%	58%
February 2006	45%	66%
March 2006	56%	74%
April 2006	63%	83%
<b>May 2006</b>	<b>75%</b>	<b>91%</b>

## CONGRATULATIONS TO NEW FLORIDA C.T.R. RECIPIENTS!

- Gary M. Levin** - Coral Springs, FL
- Adela M. Douglas** – Hollywood, FL
- Paulo Pinheiro** – Miami, FL
- Melissa K. Blakley** - Orange City, FL
- Kimberly A. Gavin** - Ormond Beach, FL
- Shamblin M. Knight** - St. Petersburg, FL
- Leah R. Gnauck** – Seminole, FL
- Kioka T. Walcott** – Tampa, FL
- Rhonda L. Buchenhain** – Wesley Chapel, FL
- Pamela D. Gantt** – Winter Haven, FL



### Register

A joint project of the Sylvester Comprehensive Cancer Center  
and the Florida Department of Health

Miller School of Medicine • University of Miami  
PO Box 016960 (D4-11) • Miami, FL 33101  
305-243-4600 • <http://fcds.med.miami.edu>

*Principle Investigator*  
Edward J. Trapido, ScD

*Project Director*  
Lora Fleming, MD, PhD

*Deputy Project Director*  
Jill A. MacKinnon, PhD, CTR

*Administrative Director*  
Gary M. Levin, CTR

*Editorial Staff*  
FCDS Staff

*Contributors*  
Megsys C. Herna, BA, CTR; Betty Fernandez; Jill  
MacKinnon, PhD, CTR

*Graphics Designer*  
Bleu Thompson

The FCRA/FCDS Task Force is actively working on many issues that all registrars are facing. If you have any questions, issues or suggestions that you would like the task force to review, please email them to [taskforce@fcra.org](mailto:taskforce@fcra.org).

The task force meets the first Thursday of every month. We will respond back to your inquiries as quickly as possible.